ENHANCED BIOCOMPATIBLE NON-POROUS BLOOD OXYGENATORS

增强型生物相容性无孔血氧发生器

• 批准号: 6141764
• 负责人: John J Bowser
• 金额: $ 10万
• 依托单位: COMPACT MEMBRANE SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2002-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6141764
• 关键词: artificial membranes; biomaterial compatibility; biotechnology; blood oxygenator; oxygen transport; polymers; surface coating; technology /technique development

Membrane based blood oxygenators are successfully used for cardiopulmonary by-pass (CPB) surgery. A number of programs are evaluating long-term membrane based blood oxygenators for artificial lungs and acute respiratory distress syndrome (ARDS). For both short- term use (CPB) and long-term use (ARDS), there is a need for enhanced blood compatible surfaces. Examples of two coating systems that are presently used to enhance blood compatibility are Avecor's Trillium and Medtronic's Carmeda. While both of these systems have some success in enhancing blood compatibility, the success is limited. Also, they tend to reduce gas (oxygen) flux and most importantly they are prone to wetting out. Compact Membrane Systems (CMS) proposes the development of a novel non-porous surface having excellent (1) wet-out resistance, (2) gas flux, and (3) blood compatibility. Enhanced blood compatibility will be based on known blood biocompatible systems. In Phase I, CMS will develop these novel structures and demonstrate enhanced performance in an in-vitro environment. PROPOSED COMMERCIAL APPLICATIONS: Successful completion of this project will significantly improve the treatment of the 500,000 CPB surgeries per year. It will also be a cornerstone in improving the potential of long-term therapy associated with ARDS.

膜式血氧机已成功应用于体外循环手术。许多项目正在评估长期使用基于膜的血液氧合器治疗人工肺和急性呼吸窘迫综合征(ARDS)。无论是短期使用(CPB)还是长期使用(ARDS)，都需要增强血液相容性表面。目前用于增强血液相容性的两种涂层系统的例子是Aveor的Trillium和美敦力的Carmeda。虽然这两个系统在提高血液相容性方面都取得了一些成功，但成功是有限的。此外，它们往往会减少气体(氧气)的流量，最重要的是，它们容易被湿化。紧凑型膜系统(CMS)提出了一种新型无孔表面的开发，该表面具有优异的(1)耐湿出、(2)气体通量和(3)血液相容性。增强血液相容性将基于已知的血液生物相容性系统。在第一阶段，CMS将开发这些新的结构，并在体外环境中展示增强的性能。拟议的商业应用：该项目的成功完成将大大改善每年500,000例CPB手术的治疗。它也将是提高与ARDS相关的长期治疗潜力的基石。